What is Oncotelic Therapeutics Inc's earnings per share (EPS)?

Oncotelic Therapeutics Inc (OTLC) reported diluted earnings per share of $0.59 for fiscal year 2026. This represents a 6000.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Oncotelic Therapeutics Inc Financials

OTLC

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Oncotelic Therapeutics Inc (OTLC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI OTLC FY2025 2026-05-14

Accounting gains rebuilt the balance sheet, but operations still burn cash and liquidity remains unusually tight.

From FY2024 to FY2025, equity expanded sharply and debt-to-equity dropped to 0.5x. Yet operating cash flow stayed negative at -$1.4M and cash ended at just $88.9K, meaning solvency improved on paper while day-to-day liquidity did not.

FY2025's net income of $249.3M sits far away from the operating loss of -$3.2M. When reported profit and operating performance diverge that widely, the year's earnings are being shaped by non-operating or non-cash items rather than by a core business that is throwing off cash, so the income statement overstates how much fresh liquidity the year actually created.

The company still looks externally financed: operating cash flow was negative in FY2024 and FY2025, while financing cash flow was positive in both years. With a current ratio of 0.07x and only $1.2M of current assets, near-term obligations are not supported by a normal working-capital cushion, which makes continued access to outside capital more important than the headline equity base suggests.

Financial Health Signals

Financial health score pending refresh

We are recalculating Oncotelic Therapeutics Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Oncotelic Therapeutics Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality Low Quality

-0.01x

For every $1 of reported earnings, Oncotelic Therapeutics Inc generates $-0.01 in operating cash flow (-$1.4M OCF vs $249.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

$249.3M

YoY+5610.7%

Oncotelic Therapeutics Inc reported $249.3M in net income in fiscal year 2026. This represents an increase of 5610.7% from the prior year.

EPS (Diluted)

$0.59

YoY+6000.0%

Oncotelic Therapeutics Inc earned $0.59 per diluted share (EPS) in fiscal year 2026. This represents an increase of 6000.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$89K

YoY+3.2%

5Y CAGR-28.5%

10Y CAGR-43.6%

Oncotelic Therapeutics Inc held $89K in cash against $0 in long-term debt as of fiscal year 2026.

Dividends Per Share

N/A

Shares Outstanding

443M

YoY+8.7%

Oncotelic Therapeutics Inc had 443M shares outstanding in fiscal year 2026. This represents an increase of 8.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

94.9%

YoY+149.7pp

5Y CAGR+175.6pp

10Y CAGR+148.7pp

Oncotelic Therapeutics Inc's ROE was 94.9% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is up 149.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$4K

5Y CAGR-74.8%

10Y CAGR-53.4%

Oncotelic Therapeutics Inc invested $4K in research and development in fiscal year 2026.

Share Buybacks

N/A

Capital Expenditures

N/A

OTLC Income Statement

Metric	FY26	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	$70K	N/A	N/A	$1.7M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4K	N/A	$61K-91.9%	$757K-79.3%	$3.7M-15.0%	$4.3M
SG&A Expenses	$3.2M+746.3%	$376K-34.5%	$574K-88.2%	$4.9M-11.2%	$5.5M+8.8%	$5.0M
Operating Income	-$3.2M+10.9%	-$3.6M+46.2%	-$6.6M+31.6%	-$9.7M-6.5%	-$9.1M-20.3%	-$7.6M
Interest Expense	N/A	N/A	$1.0M-64.8%	$3.0M+48.3%	$2.0M+0.2%	$2.0M
Income Tax	$111.5M	N/A	N/A	N/A	N/A	N/A
Net Income	$249.3M+5610.7%	-$4.5M+42.8%	-$7.9M-255.1%	$5.1M+154.3%	-$9.4M+1.2%	-$9.5M
EPS (Diluted)	$0.59+6000.0%	$-0.01+50.0%	$-0.02-300.0%	$0.01+133.3%	$-0.03	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$795	N/A	N/A	$2970.0%	$297	N/A	$480+90.5%	$252
SG&A Expenses	$1.9M	N/A	$491K+647.0%	$66K-34.9%	$101K	N/A	$80K-16.7%	$96K
Operating Income	-$1.9M	N/A	-$491K-644.2%	-$66K+34.7%	-$101K	N/A	-$3.3M-3296.9%	-$97K
Interest Expense	$9K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.2M	N/A	-$1.0M-476.9%	$278K+193.0%	-$299K	N/A	-$3.3M-1474.8%	-$210K
EPS (Diluted)	$0.00	N/A	N/A	$0.00	$0.00	N/A	$-0.01	$0.00

OTLC Balance Sheet

Metric	FY26	FY24	FY23	FY22	FY21	FY20
Total Assets	$393.1M+1373.5%	$26.7M-11.1%	$30.0M-16.9%	$36.1M+53.0%	$23.6M-0.2%	$23.7M
Current Assets	$1.2M+792.8%	$134K-50.6%	$272K-10.4%	$303K-51.7%	$627K+1.9%	$616K
Cash & Equivalents	$89K+3.2%	$86K-49.5%	$170K-29.4%	$241K-57.5%	$569K+20.0%	$474K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$51K+170.5%	$19K0.0%	$19K-3.9%	$20K0.0%	$20K0.0%	$20K
Goodwill	$2.8M0.0%	$2.8M-53.4%	$6.0M-50.4%	$12.1M-42.7%	$21.1M0.0%	$21.1M
Total Liabilities	$131.4M+584.2%	$19.2M+4.3%	$18.4M+8.7%	$16.9M+8.1%	$15.7M+31.7%	$11.9M
Current Liabilities	$18.1M-5.5%	$19.2M+16.3%	$16.5M-2.5%	$16.9M+9.5%	$15.5M+38.2%	$11.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$262.8M+3084.3%	$8.3M-32.0%	$12.1M-37.5%	$19.4M+144.0%	$8.0M-32.4%	$11.8M
Retained Earnings	$211.2M+655.3%	-$38.0M-13.5%	-$33.5M-29.3%	-$25.9M+16.4%	-$31.0M-43.4%	-$21.6M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$394.0M+0.2%	$393.1M+1296.1%	$28.2M+5.5%	$26.7M0.0%	$26.7M0.0%	$26.7M-0.4%	$26.8M-10.5%	$29.9M
Current Assets	$2.1M+72.3%	$1.2M-25.7%	$1.6M+1072.3%	$138K+10.1%	$125K-6.9%	$134K-43.9%	$239K+24.5%	$192K
Cash & Equivalents	$64K-28.4%	$89K-78.3%	$409K+364.7%	$88K+11.2%	$79K-8.1%	$86K-42.2%	$149K+106.4%	$72K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$2K-96.0%	$51K+1190.8%	$4K-79.0%	$19K0.0%	$19K0.0%	$19K0.0%	$19K0.0%	$19K
Goodwill	$2.8M0.0%	$2.8M0.0%	$2.8M0.0%	$2.8M0.0%	$2.8M0.0%	$2.8M0.0%	$2.8M-53.4%	$6.0M
Total Liabilities	$131.7M+0.3%	$131.4M+554.2%	$20.1M+4.1%	$19.3M-1.0%	$19.5M+1.5%	$19.2M+2.9%	$18.7M+1.2%	$18.4M
Current Liabilities	$18.4M+1.4%	$18.1M-9.6%	$20.1M+4.1%	$19.3M-1.0%	$19.5M+1.5%	$19.2M+17.4%	$16.4M+0.9%	$16.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$263.3M+0.2%	$262.8M+2803.2%	$9.1M+9.0%	$8.3M+3.5%	$8.0M-2.8%	$8.3M-6.8%	$8.9M-27.2%	$12.2M
Retained Earnings	$209.0M-1.0%	$211.2M+640.1%	-$39.1M-2.8%	-$38.1M+0.7%	-$38.3M-0.8%	-$38.0M-1.6%	-$37.4M-9.7%	-$34.1M

OTLC Cash Flow Statement

Metric	FY26	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$1.4M-86.8%	-$740K+44.0%	-$1.3M+9.1%	-$1.5M+67.2%	-$4.4M-57.7%	-$2.8M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$1.4M+111.3%	$656K-47.5%	$1.3M+11.1%	$1.1M-75.2%	$4.5M+40.5%	$3.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$342K+56.3%	-$783K-155.0%	-$307K-143.4%	-$126K+24.4%	-$167K-60.7%	-$104K+27.5%	-$143K+45.3%	-$262K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$317K-31.5%	$463K-26.3%	$628K+365.2%	$135K-15.6%	$160K+290.2%	$41K-81.4%	$220K+51.7%	$145K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

OTLC Financial Ratios

Metric	FY26	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-9497.2%	N/A	N/A	-435.7%
Net Margin	N/A	N/A	-11290.1%	N/A	N/A	-545.9%
Return on Equity	94.9%+149.7pp	-54.8%+10.3pp	-65.1%-91.4pp	26.3%+144.3pp	-118.0%-37.3pp	-80.7%
Return on Assets	63.4%+80.4pp	-17.0%+9.4pp	-26.3%-40.4pp	14.1%+53.9pp	-39.8%+0.4pp	-40.2%
Current Ratio	0.07+0.1	0.010.0	0.020.0	0.02-0.0	0.04-0.0	0.06
Debt-to-Equity	0.50-1.8	2.33+0.8	1.52+0.6	0.87-1.1	1.97+1.0	1.01
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-0.8%	N/A	-11.6%-14.9pp	3.4%+7.1pp	-3.7%	N/A	-37.3%-35.6pp	-1.7%
Return on Assets	-0.6%	N/A	-3.7%-4.8pp	1.0%+2.2pp	-1.1%	N/A	-12.3%-11.6pp	-0.7%
Current Ratio	0.11+0.0	0.07-0.0	0.08+0.1	0.010.0	0.010.0	0.010.0	0.010.0	0.01
Debt-to-Equity	0.500.0	0.50-1.7	2.22-0.1	2.32-0.1	2.43+0.1	2.33+0.2	2.11+0.6	1.52
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: The current ratio is below 1.0 (0.07), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Resverlogix RVXCF

$22.2M

Finch Therapeutics Group, Inc. FNCH

$5.0M

Biomind Labs Inc BMNDF

$3.9M

ACCUSTEM SCIENCES INC ACUT

$3.2M

Harvard Apparatus Regenerative Technology Inc. HRGN

$18.5M

Frequently Asked Questions

Is Oncotelic Therapeutics Inc profitable?

Yes, Oncotelic Therapeutics Inc (OTLC) reported a net income of $249.3M in fiscal year 2026.

What is Oncotelic Therapeutics Inc's return on equity (ROE)?

Oncotelic Therapeutics Inc (OTLC) has a return on equity of 94.9% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Oncotelic Therapeutics Inc's operating cash flow?

Oncotelic Therapeutics Inc (OTLC) generated -$1.4M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Oncotelic Therapeutics Inc's total assets?

Oncotelic Therapeutics Inc (OTLC) had $393.1M in total assets as of fiscal year 2026, including both current and long-term assets.

How much does Oncotelic Therapeutics Inc spend on research and development?

Oncotelic Therapeutics Inc (OTLC) invested $4K in research and development during fiscal year 2026.

How many shares does Oncotelic Therapeutics Inc have outstanding?

Oncotelic Therapeutics Inc (OTLC) had 443M shares outstanding as of fiscal year 2026.

What is Oncotelic Therapeutics Inc's current ratio?

Oncotelic Therapeutics Inc (OTLC) had a current ratio of 0.07 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.

What is Oncotelic Therapeutics Inc's debt-to-equity ratio?

Oncotelic Therapeutics Inc (OTLC) had a debt-to-equity ratio of 0.50 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Oncotelic Therapeutics Inc's return on assets (ROA)?

Oncotelic Therapeutics Inc (OTLC) had a return on assets of 63.4% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Oncotelic Therapeutics Inc's cash runway?

Based on fiscal year 2026 data, Oncotelic Therapeutics Inc (OTLC) had $89K in cash against an annual operating cash burn of $1.4M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Oncotelic Therapeutics Inc's Piotroski F-Score?

Oncotelic Therapeutics Inc (OTLC) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Oncotelic Therapeutics Inc's earnings high quality?

Oncotelic Therapeutics Inc (OTLC) has an earnings quality ratio of -0.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.